This is to inform that due to some circumstances beyond the organizer control, “International Conference on Medicinal Chemistry, Computer Aided Drug Design and Delivery” (MCADD 2023) Hybrid event during September 14-16, 2023 at Valencia, Spain has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at medicinal-chemistry@magnusconference.com or call + 1 (702) 988 2320.
The use of drugs to treat human disease can be traced all the way back to our evolutionary forefathers. Drugs are powerful chemicals with a high potential for harm if they are misused or overused. Pharmaceuticals can spark debates regarding their relative dangers and advantages in specific contexts, even when taken correctly. The use of modern middlemen in the distribution of the most powerful pharmaceuticals, such as physicians or pharmacists, increases the risk of conflict between those who control the resource and those who want access to it. Because of the size and importance of the pharmaceutical–industrial complex, people whose interests lie in promoting and expanding pharmaceutical use in society wield disproportionate power. The high cost of some pharmaceuticals makes equal allocation difficult, and the concentration of pharmaceutical power in Western, industrialised countries encourages disproportionately more research and drug discovery for diseases that affect the wealthier countries. The increasing sophistication of pharmacological action calls into question the traditional approach of utilising medications to treat pathological illnesses and processes, and opens the possibility of pharmaceuticals being used for lifestyle and enhancement purposes.
Title : A qsar survey on tyrosine kinase inhibitors
Atefeh Hajiagha Bozorgi, Faculty of pharmacy, Iran (Islamic Republic of)
Title : Abbott diagnostics: COVID-19 inactivation, nucleocapsid antigen automated immunoassay development, and variant testing for automated and lateral flow assays binaxnow™ and panbio™
Philip M Hemken, Abbott Laboratories, United States
Title : Synthesis, antibacterial activity of 3-amino 5-methoxyl-2-methyl quinazolin-4(3H)-one an amino-6-methoxyl-2-methyl of 4H–benzo[d] [1,3]–oxazine–4–one
Osarumwense Peter Osarodion, Ondo State University of Sciences and Technology, Nigeria
Title : Tackling mycobacterium tuberculosis resistance with tailored isatin-pyrimidine hybrids enoyl acyl carrier protein reductase (Inha)
Amgad Albohy, The British University in Egypt (BUE), Egypt
Title : Transition metal complexes/Organometallic compounfs as anticancer drugs
Prakash kinthda, Nims university,jaipur,rajasthan, India
Title : New n-ribosides and n-mannosides of rhodanine derivatives with anticancer activity on leukaemia cell line: Design, synthesis, dft and molecular modelling studies
Ahmed, Kafrelsheikh University, Egypt